Elan Moves Ahead With J&J Deal, But Does Biogen Really Approve?

Is it over? Elan Corp. and Johnson & Johnson said Sept. 17 they successfully closed their deal to share Alzheimer disease programs

More from Archive

More from Pink Sheet